Other Information Technology · Wilmington, DE · Founded 2024 · Privately Held (backing)
Developer of a biotech platform designed to apply generative artificial intelligence to biological data for advancing drug discovery and development. Converge Bio is based in Wilmington, DE and was founded in 2024. It was valued at $90 million at its early-stage round in Jan 2026, the last priced event on record. It has raised $30.5 million across 1 recorded round; the latest was a $25 million Series A in Jan 2026.
PMV mark · valuation
$90.0M
Oct 2026
Priced at
its early-stage round
Jan 2026
Total raised
$30.5M
Last round
Early Stage VC (Series A)
Jan 2026
Team — not yet on record
No current team members for Converge Bio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Converge Bio with a free account
·Watch Converge Bio: the Monday email on marks, rounds and moves
